Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Abbott | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Abbott

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott

4Q Revenues: $7.2 billion (+16%)

4Q Earnings: $1.2 billion (loss of $476 million 4Q06)*

FY Revenues: $25.9 billion (+15%)

FY Earnings: $3.6 billion (+110%)

Comments: Worldwide pharmaceutical sales in the quarter were $4.2 billion, up 19%. U.S. pharma sales increased 17% and international sales were up 21%, driven by Humira, Kaletra and TriCor, as well as Niaspan sales of $179 million. Humira sales in 4Q07 and FY07 were $954 million (+54%) and $3 billion (+50%), respectively. 4Q07 and FY07 Kaletra sales were $371 million (+25%) and $1.3 billion (+17%), respectively. Tricor sales were up 20% to $392 million in the quarter and up 16% for the year to $1.2 billion. R&D expenses were $662 million in the quarter (+11%) and $2.5 billion for the year (+11%).

*4Q2006 earnings exclude after-tax charges of $1.3 billion for acquired in-process and collaborations R&D primarily related to the Kos acquisition.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters